Company Overview
GRAIL, Inc. operates as a commercial-stage healthcare entity that delivers multi-cancer early detection testing and associated services to both domestic and international markets. The company specifically offers Galleri, a screening test designed for asymptomatic individuals over the age of 50, alongside a diagnostic aid intended to accelerate cancer detection processes. This business model places GRAIL within the Healthcare sector, specifically targeting the Diagnostics & Research industry, where it leverages advanced technology to identify malignancies before symptoms appear. In terms of scale, the company possesses a market capitalization of $1.92 billion and reports annual revenue of $147.17 million based on trailing twelve-month figures. With an employee count of 910, these financial metrics indicate that GRAIL is a mid-sized biotechnology firm with significant operational capacity, yet the market cap relative to revenue suggests the market values the company primarily on its future potential rather than current cash flows, reflecting the high-risk, high-reward nature of its diagnostic testing business.
Financial Health
The company reported a revenue of $147.17 million over the trailing twelve months, yet it recorded a net income of $-408,351,008 and an EBITDA of $-377,852,992, revealing a substantial gap between top-line sales and bottom-line profitability. This significant disparity indicates a heavy cost structure where operating expenses, likely driven by research and development and commercialization efforts, far exceed the gross margins generated from product sales. GRAIL generated free cash flow of $-108,893,128, which signifies that the company is currently burning cash to fund its growth initiatives rather than generating liquidity for shareholders or debt repayment. The company maintains a cash balance of $904.43 million against total debt of $54.86 million, resulting in a debt-to-equity ratio of 2.13. Despite the high leverage indicated by the debt-to-equity figure, the balance sheet appears robust given the cash reserves vastly outweighing the debt obligation. Furthermore, the current ratio stands at 11.97, which indicates an exceptionally strong short-term liquidity position and the ability to cover current liabilities more than eleven times over. Return on Equity is -16.1% and Return on Assets is -11.3%, metrics that reveal management has not yet achieved positive returns on its capital base, a common characteristic for early-stage commercial healthcare companies investing heavily in pipeline expansion.
Valuation Assessment
Valuation metrics for GRAIL present a complex picture due to the lack of traditional profitability multiples, with the P/E Ratio (TTM) listed as N/A and a Forward P/E of -5.18. The negative forward P/E implies that analysts or market data sources expect the company to remain unprofitable in the near term, preventing the use of standard earnings-based valuation models. Instead, investors look to the Price to Book ratio of 0.73, which indicates the stock is trading below its book value, suggesting the market is pricing in significant risks or potential asset liquidation scenarios. The Price to Sales ratio is elevated at 13.06, while the EV/EBITDA stands at -2.84, suggesting that valuation is driven entirely by revenue growth expectations rather than earnings power. The stock has a 52-Week High of $118.84 and a 52-Week Low of $20.44, creating a trading range that highlights extreme volatility. Without a specific current price provided in the available facts to calculate the exact percentage distance from the highs or lows, the wide spread between $118.84 and $20.44 underscores the speculative nature of the investment. Additionally, the Beta is N/A, meaning volatility data relative to the broader market is not currently available for this specific ticker in the provided dataset.
Growth & Income
GRAIL is demonstrating robust top-line expansion with a Revenue Growth (YoY) of 14.0%, while Earnings Growth (YoY) is N/A due to the company's ongoing losses. The absence of earnings growth data confirms that revenue growth is currently the sole driver of expansion, as the negative net income prevents any meaningful year-over-year earnings improvement. Regarding income distributions, the company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This lack of dividend payments is typical for companies with negative net income and confirms that GRAIL reinvests all available capital back into operations, research, and market development rather than returning cash to shareholders. Consequently, the overall growth and income profile is defined by aggressive revenue scaling to capture market share in the early detection space, with no current income yield to offset the risks associated with the high Price to Sales multiple and negative free cash flow.